Anti-staphylococcal activity of indolmycin, a potential topical agent for control of staphylococcal infections

Journal of Antimicrobial Chemotherapy

Volumn 54, Issue 2, 2004, Pages 549-552

  Hurdle, Julian G ^a   O'Neill, Alex J ^a   Chopra, Ian ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Antibiotics; Control of MRSA carriage; Dermatological infections; Staphylococcus aureus

Indexed keywords

ANTIBIOTIC AGENT; DRUG METABOLIZING ENZYME; FUSIDIC ACID; INDOLMYCIN; METICILLIN; PSEUDOMONIC ACID; TRYPTOPHAN TRANSFER RNA LIGASE; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIOSTASIS; BACTERIUM CARRIER; BACTERIUM ISOLATE; BACTERIUM MUTANT; CONTROLLED STUDY; CROSS RESISTANCE; DRUG TARGETING; GENE LOCUS; GENE MUTATION; GENETIC IDENTIFICATION; GENOTYPE PHENOTYPE CORRELATION; INFECTION CONTROL; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STAPHYLOCOCCUS INFECTION;

ANTI-INFECTIVE AGENTS, LOCAL; BACILLUS STEAROTHERMOPHILUS; DRUG RESISTANCE, BACTERIAL; FUSIDIC ACID; INDOLES; MUPIROCIN; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TRYPTOPHAN-TRNA LIGASE;

EID: 4444341397     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh352     Document Type: Article

References (10)

1. Ravenscroft, J. C., Layton, A. M., Eady, E. A. et al. (2003). Short-term effects of topical fusidic acid or mupirocin on the prevalence of fusidic acid resistant (FusR) Staphylococcus aureus in atopic eczema. British Journal of Dermatology 148, 1010-7.
2. Brown, E. M. & Wise, R. (2002). Fusidic acid cream for impetigo. Fusidic acid should be used with restraint. British Medical Journal 324, 1394.
3. Deshpande, L. M., Fix, A. M., Pfaller, M. A. et al. (2002). Emerging elevated mupirocin resistance rates among staphylococcal isolates in the SENTRY Antimicrobial Surveillance Program (2000): correlations of results from disk diffusion, Etest and reference dilution methods. Diagnostic Microbiology and Infectious Disease 42, 283-90.
4. Werner, R. G. (1980). Uptake of indolmycin in gram-positive bacteria. Antimicrobial Agents and Chemotherapy 18, 858-62.
5. Kanamaru, T., Nakano, Y., Toyoda, Y. et al. (2001). In vitro and in vivo antibacterial activities of TAK-083, an agent for treatment of Helicobacter pylori infection. Antimicrobial Agents and Chemotherapy 45,2455-9.
6. Oliva, B., Miller, K., Caggiano, N. et al. (2003). Biological properties of novel antistaphylococcal quinoline-indole agents. Antimicrobial Agents and Chemotherapy 47, 458-66.
7. Hurdle, J. G., O'Neill, A. J. & Chopra, I. (2004). The isoleucyl-tRNA synthetase mutation V588F conferring mupirocin resistance in glycopeptide-intermediate Staphylococcus aureus is not associated with a significant fitness burden. Journal of Antimicrobial Chemotherapy 53, 102-4.
8. Kitabatake, M., Ali, K., Demain, A. et al. (2002). Indolmycin resistance of Streptomyces coelicolor A3(2) by induced expression of one of its two tryptophanyl-tRNA synthetases. Journal of Biological Chemistry 277, 23882-7.
9. Tao, J. S. & Schimmel, P. (2000). Inhibitors of aminoacyl-tRNA synthetases as novel anti-infectives. Expert Opinion on Investigational Drugs 9, 1767-75.
10. Retailleau, P., Huang, X., Yin, Y. et al. (2003). Interconversion of ATP binding and conformational free energies by tryptophanyl-tRNA synthetase: structures of ATP bound to open and closed, pre-transition-state conformations. Journal of Molecular Biology 325, 39-63.